J&J’s Nipocalimab Data Signals the FcRn Gold Rush Has a Real Leader
J&J's nipocalimab cut SLE disease activity in Phase 2 JASMINE—and with Phase 3 already recruiting, FcRn blockade is becoming...
Nipocalimab
J&J's nipocalimab cut SLE disease activity in Phase 2 JASMINE—and with Phase 3 already recruiting, FcRn blockade is becoming...